Treatment-related leukopenia in anal cancer patients associated with worse outcome: results of a retrospective cohort study

Figures & data

Table 1. Univariate and multivariate Cox analyses for local recurrence and distant recurrence.

Variable	Local recurrence				Distant recurrence
	Univariate		Multivariate		Univariate		Multivariate
	HR	p Value	HR	p Value	HR	p Value	HR	p Value
Male gender	1.98	0.16	–	–	1.51	0.29	–	–
Active smoking	0.73	0.57	–	–	0.49	0.15	–	–
Immunosuppressive disorders	2.83	0.04	3.46	0.03	2.53	0.02	2.62	0.03
T4	2.50	0.045	3.76	0.008	2.02	0.051	1.93	0.09
Primary tumor size ≥ 4 cm	1.64	0.38	–	–	1.97	0.13	–	–
N+	0.93	0.86	–	–	1.18	0.63	–	–
Time to treatment initiation ≥ 62 d	1.81	0.21	–	–	1.29	0.50	–	–
RTT ≥5 d longer than optimal	2.36	0.08	2.88	0.04	1.83	0.14	–	–
No concomitant chemotherapy	1.51	0.51	–	–	1.41	0.48	–	–
Dose reduction of chemotherapy	0.24	0.17	–	–	1.12	0.81	–	–
Pretreatment hemoglobin < 120 g/L	0.83	0.71	–	–	0.51	0.13	–	–
Pretreatment leukocyte count > 10 × 10^9/L	2.10	0.13	–	–	1.31	0.53	–	–
Fall of hemoglobin > 30 g/L during radiotherapy	2.48	0.056	1.36	0.56	2.11	0.04	1.32	0.50
Gastrointestinal G3 + toxicity	1.73	0.23	–	–	1.50	0.25	–	–
White blood cell G3 + toxicity	4.38	0.009	4.48	0.01	2.46	0.02	2.20	0.045
Charlson comorbidity index ≥1	0.87	0.77	–	–	1.43	0.30	–	–

HR: hazard ratio; RTT: radiation treatment time

Bold values represent p values <0.05.

Table 2. Significant predictors for all endpoints on multivariate Cox analyses.

Endpoints and variables	HR (95% CI)	p Value
Local recurrence
Immunosuppressive disorders	3.5 (1.1–10.5)	0.03
T4	3.8 (1.4–10.0)	0.008
RTT ≥ 5 d longer than optimal	2.9 (1.0–8.0)	0.04
White blood cell G3+ toxicity	4.5 (1.3–14.8)	0.01
Distant recurrence
Immunosuppressive disorders	2.6 (1.1–6.1)	0.03
White blood cell G3+ toxicity	2.2 (1.0–4.8)	0.045
Overall survival
Male gender	4.6 (2.0–10.3)	<0.001
Time to treatment initiation ≥ 62 d	2.5 (1.2–5.3)	0.01
RTT ≥ 5 d longer than optimal	3.2 (1.3–7.8)	0.01
White blood cell G3+ toxicity	3.2 (1.4–7.1)	0.004
Anal cancer specific survival
Male gender	3.3 (1.2–8.7)	0.02
Immunosuppressive disorders	4.1 (1.6–10.7)	0.003
No concomitant chemotherapy	4.0 (1.1–15.0)	0.04
White blood cell G3+ toxicity	3.7 (1.2–11.2)	0.02
Non- -->anal cancer death
Male gender	4.9 (1.5–16.5)	0.01
Gastrointestinal G3+ toxicity	4.0 (1.3–12.7)	0.02

RTT: radiation treatment time